Related Experiment Video
Updated: Sep 17, 2025

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Platelet aggregation and its modulation using antithrombotic agents
Nandini Srivastava1, Kaushik Ghanshyambhai Khatrani2, Bansari Yagnik Tank3
1Department of Physiology, Maharshi Vashishtha Autonomous State Medical College, Basti, Uttar Pradesh, India.
Abstract:
Aggregation of platelets using three antithrombotic agents such as Ticagrelor Derivative (TD-101), Rivaroxaban Analog (RA-202) and Apixaban Variant (AV-303) were assessed. All the three agents showed dose-dependent inhibitory effects in platelet aggregation where AV-303 exhibited the strongest inhibitory activity according to light transmission aggregometry. The statistical analysis showed distinctions (p < 0.05) between groups receiving treatment and controls. This opens possibilities for medical applications in thrombotic disorder treatment. It should be noted that additional animal tests and clinical studies are needed to validate effectiveness and safety of these agents.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

